Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

BACKGROUND AND PURPOSE: We conducted preclinical and clinical studies to examine the pharmacological, particularly cardiac, effects of amiselimod (MT‐1303), a second‐generation sphingosine 1‐phosphate (S1P) receptor modulator, designed to reduce the bradycardia associated with fingolimod and other S...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugahara, Kunio, Maeda, Yasuhiro, Shimano, Kyoko, Mogami, Akira, Kataoka, Hirotoshi, Ogawa, Kei, Hikida, Kumiko, Kumagai, Hiroshi, Asayama, Mahoko, Yamamoto, Toshinobu, Harada, Tomohiko, Ni, Pingping, Inoue, Shinsuke, Kawaguchi, Atsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221453/
https://www.ncbi.nlm.nih.gov/pubmed/27714763
http://dx.doi.org/10.1111/bph.13641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221453/
https://www.ncbi.nlm.nih.gov/pubmed/27714763
http://dx.doi.org/10.1111/bph.13641

Ejemplares similares